Background {#Sec1}
==========

Staphylococci are the first etiologic agents of bone and joint infection (BJI). Methicillin-susceptible *Staphylococcus aureus* (MSSA) is predominant and antistaphylococcal penicillins such as nafcillin, oxacillin and cloxacillin are the backbone molecules for the initial antimicrobial therapy \[[@CR1], [@CR2]\]. Nevertheless, glycopeptide alternative, including vancomycin or teicoplanin, remains frequently used for several reasons: i) although hospital diffusion of methicillin-resistant clones of *S. aureus* (MRSA) is currently controlled in France, MRSA still accounts for 20 % of *S. aureus* isolates involved in BJI \[[@CR3]\]; ii) half of staphylococcal BJI are caused by coagulase negative staphylococci (CNS), among which methicillin resistance has continuously increased in the past years to presently reach 50 % of isolates \[[@CR3]\]; and iii) antistaphylococcal penicillins are the first cause of antimicrobial-related adverse events during long-term treatment of staphylococcal BJI \[[@CR4]\], in case of which glycopeptides are the first alternative. If vancomycin is largely prescribed in this context, teicoplanin could theoretically represent an acceptable alternative in BJI as studies have shown a comparable efficacy compared to vancomycin in various other conditions \[[@CR5]\] and an improved safety profile with fewer renal toxicity \[[@CR6]\], as well as the possibility of daily subcutaneous injection, of particular interest for outpatient parenteral antimicrobial therapy (OPAT). In addition, various studies have shown that teicoplanin pharmacodynamic profile was superior compared to vancomycin regarding bone diffusion \[[@CR7], [@CR8]\]. Few studies have investigated the use of teicoplanin in BJI, particularly through subcutaneous administration. The present study assesses the efficacy and tolerance of teicoplanin in *S. aureus* BJI, especially focusing on subcutaneous use.

Methods {#Sec2}
=======

Inclusion criteria and data collection {#Sec3}
--------------------------------------

A retrospective single-center observational cohort study (2001 to 2011) was conducted including all consecutive patients managed at our institution receiving teicoplanin as part of *S. aureus* BJI treatment. Patients diagnosed with staphylococcal BJI were identified by cross-referencing the prospective maintained databases of the regional referral center for BJI and the bacteriology laboratory, which list exhaustively all strains isolated from osteoarticular samples since 2001. Patients with diabetic foot- and decubitus ulcer-related BJI were excluded, as they require a specific management \[[@CR9]\]. If patients presented more than one osteoarticular infected site, they were considered as independent events for cohort description and outcome analysis, but pooled for tolerance and pharmacologic evaluation. For each patient, data were collected from medical records, nursing charts and biological software in an anonymous standardized case report form. All available trough teicoplanin plasmatic levels (C~min~) in the first 14 days of treatment were recorded.

Definitions {#Sec4}
-----------

BJI diagnosis was based upon the existence of clinical and biological evidences of infection, and at least one reliable bacteriological sample positive for *S. aureus* (i.e., percutaneous joint fluid aspiration, surgical sample, and/or blood culture). BJI were classified according to: i) the existence of orthopedic implant (i.e. joint prosthesis, peripheral or vertebral osteosynthesis); and ii) progression of infection, differentiating acute (≤3 weeks) *versus* chronic (\>3 weeks) infection, calculated from the presumed date of inoculation (i.e., date of device implantation for postoperative orthopaedic device-related infection (ODI), or date of symptom onset for native BJI) up to diagnosis.

The modified Charlson's comorbidity index was calculated as previously described \[[@CR10]\]. Immunosuppression was defined as: i) corticosteroid therapy \>10 mg of prednisone per day or equivalent for at least 3 months; ii) immunosuppressive drug(s) during the two last months before BJI onset; or iii) chemotherapy for hematological malignancy or solid tumor.

A C~min~ \>15 mg/L was taken as an acceptable therapeutic target. Patients with a C~min~ \>25 mg/L were considered as overexposure.

Teicoplanin-related adverse events (AE) occurring during follow-up were notified and classified according to the Common Terminology Criteria for Adverse Events (CTCAE, National Cancer Institute, 2003). Teicoplanin accountability in the AE occurrence was left to the clinician appreciation, with the help of a pharmacovigilance specialist in doubtful cases.

Treatment failure was defined as persisting infection under appropriate antimicrobial therapy, relapse after the interruption of antimicrobial therapy, necessity of surgical revision on the account of persisting septic focus ≥5 days after the first intervention, superinfections, and/or fatal outcome if BJI-related.

Teicoplanin administration {#Sec5}
--------------------------

For intravenous (IV) administration, each dose was diluted in 100 mL of isotonic saline solution and administrated over a 30-min period. For subcutaneous (SC) injections, each dose was diluted in 50 mL of isotonic saline solution and delivered by a nurse during a 30- to 60-min gravity infusion using a butterfly disposable needle.

Statistical analysis {#Sec6}
--------------------

Descriptive statistics were used to estimate the frequencies of the study variables, described as percentages (%) for dichotomous variables, and medians (interquartile range (IQR)) for continuous variables. For the percentage calculation of each variable, the number of missing values was excluded from the denominator. Non-parametric statistical methods were used to compare the study groups (Chi-squared test, Fisher exact test and Mann--Whitney *U* test), as appropriate. Determinants of teicoplanin-related AE and treatment failure were assessed using binary logistic regression, including the clinically relevant variables in each model, and expressed by their Odd ratio (OR) and 95 % confidence intervals (95 % CI). Clinically pertinent variables with a *p*-value \<0.15 in the univariate analysis were included in the final multivariate models. A value of *p* \<0.05 was considered as significant. All analyses were performed using SPSS software version 19.0 (SPSS, Chicago, IL).

Results {#Sec7}
=======

Population characteristics {#Sec8}
--------------------------

Sixty patients were included (34 male, 56.7 %; median age, 62 years (interquartile range (IQR), 48-75), among who two and one presented three and two concomitant infected osteoarticular site, respectively. Consequently, a total of 65 episodes of BJI were analyzed, including 20 (30.8 %) native and 45 (69.2 %) orthopedic device-related (ODI) infections, and 23 (35.4 %) chronic infections. A MRSA was implicated in 11 (16.9 %) cases and 17 (26.2 %) infections were plurimicrobial. All staphylococcal isolates were susceptible to teicoplanin. A surgical procedure was performed in 50 (76.9 %) cases, predominantly in ODI (93.3 %). All patients were initially treated by a combination antimicrobial therapy. Median total duration of treatment was 26.8 (IQR, 17.7--42.8) weeks. Patients' characteristics are described in Table [1](#Tab1){ref-type="table"}.Table 1Description of the 65 included episodes of BJI and comparison between the intravenous and subcutaneous routes of administrationTotal population (*n* = 65)Intravenous administration (*n* = 51)Subcutaneous administration (*n* = 14)*p*-valueDemographics Sex (male)34 (52.3 %)27 (52.9 %)7 (50.0 %)1.000 Age (year-old)61.8 (49.0--74.0)61.8 (52.1--73.8)59.1 (39.1--75.5)0.678Comorbidities Modified CCI3 (1--5)3 (2--5)1.5 (0.3--5.8)0.478 BMI (kg/m^2^)27.0 (21.6--29.7)27.8 (22.0--31.6)24.7 (20.7--28.0)0.154 Obesity (BMI \> 30)14 (22.2 %)13 (26.5 %)1 (7.1 %)0.116 Diabetes8 (12.3 %)7 (13.7 %)1 (7.1 %)0.447 Immunosuppression11 (16.9 %)10 (19.6 %)1 (7.1 %)0.253 Chronic renal failure9 (14.8 %)6 (12.8 %)3 (21.4 %)0.338 Chronic hepatic disease2 (3.3 %)2 (4.3 %)0 (0 %)0.591 Chronic pulmonary disease15 (24.6 %)10 (21.3 %)5 (35.7 %)0.223 Congestive heart failure5 (8.1 %)3 (6.3 %)2 (14.3 %)0.314 Cerebrovascular disease4 (6.6 %)1 (2.1 %)3 (21.4 %)0.035 Peripheral artery disease5 (8.2 %)4 (8.5 %)1 (7.1 %)0.678 Neoplasic disease6 (9.8 %)6 (12.8 %)0 (0 %)0.193 Malignant hemopathy1 (1.5 %)1 (2.0 %)0 (0 %)0.785 Inflammatory systemic disease9 (14.8 %)9 (19.1 %)0 (0 %)0.079 Dementia2 (3.1 %)2 (3.9 %)0 (0 %)0.613BJI types Native BJI20 (30.8 %)16 (31.4 %)4 (28.6 %)0.559  Incl. arthritis5 (25 %)4 (25.0 %)1 (25.0 %)0.708  Incl. osteomyelitis5 (25 %)5 (31.3 %)0 (0 %)0.284  Incl. vertebral osteomyelitis10 (50 %)7 (43.8 %)3 (75.0 %)0.367 ODI45 (69.2 %)35 (68.6 %)10 (71.4 %)0.559  Incl. PJI34 (75.6 %)28 (80.0 %)6 (60.0 %)0.187  Incl peripheral osteosynthesis8 (17.8 %)6 (17.1 %)2 (20.0 %)0.579  Incl. vertebral osteosynthesis3 (6.7 %)1 (2.9 %)2 (20.0 %)0.119BJI characteristics Evolution delay (weeks)1.6 (0.1--6.7)1.6 (0.4--9.2)0.9 (0.2--3.1)0.299  Chronic BJI (\> 3 weeks)23 (35.4 %)19 (37.3 %)4 (28.6 %)0.754 Mechanism  Hematogenous30 (46.2 %)24 (47.1 %)6 (42.9 %)1.000  Inoculation32 (49.2 %)25 (49.0 %)7 (50.0 %)1.000  Contiguity3 (4.6 %)2 (3.9 %)1 (7.1 %)0.523 MRSA11 (16.9 %)9 (17.6 %)2 (14.3 %)1.000 Plurimicrobial infection17 (26.2 %)16 (31.4 %)1 (7.1 %)0.062Biological inflammatory syndrom61 (95.3 %)47 (91.0 %)14 (100 %)1.000 Maximal CRP value (mg/L)164 (92--234.3)160.2 (86.8--300.0)264.7 (143.2--332.0)0.245Local and general complications Abscess26 (40.0 %)22 (43.1 %)4 (28.6 %)0.252 Sinus tract23 (35.4 %)21 (41.2 %)2 (14.3 %)0.056 Infective endocarditis2 (3.7 %)2 (4.8 %)0 (0 %)1.000Hospitalization Length of stay (weeks)5.6 (1.9--8.9)5.8 (2.3--8.9)3.8 (1.6--8.1)0.580Surgical management50 (76.9 %)38 (74.5 %)12 (85.7 %)0.491 Debridement (native BJI)8 (40.0 %)5 (31.3 %)3 (75.0 %)0.153 Conservative procedure^a^24 (53.3 %)20 (57.1 %)4 (40.0 %)0.274 One-stage exchange^a^3 (6.7 %)2 (5.7 %)1 (10.0 %)0.539 Two-stage exchange^a^15 (33.3 %)11 (31.4 %)4 (40.0 %)0.440Antimicrobial therapy Total duration (weeks)26.8 (17.7--42.8)26.2 (17.9--41.6)28.4 (17.8--48.4)0.406 Parenteral treatment64 (98.5 %)50 (98.0 %)14 (100 %)1.000  Duration (weeks)9.4 (5.9--24.4)9.4 (6.3--25.1)10.4 (4.4--16.1)0.790 Combination therapy65 (100 %)51 (100 %)14 (100 %)NC  Duration (weeks)25.7 (16.4--45.1)25.6 (15.9--44.3)27.6 (21.3--43.2)0.442Teicoplanin use IV route51 (78.5 %)NANANA Loading dose55 (85.9 %)44 588.0 %)11 (78.6 %)0.521  Loading dose (mg/kg/12 h)5.7 (4.7--6.5)5.6 (4.7--6.5)6.0 (5.4--6.7)0.218  Number of injections5 (5--5)5 (5--5)5 (5--5) Maintenance dose (mg/kg/24 h)5.7 (4.7--6.5)5.6 (4.7--6.5)5.9 (5.1--6.8)0.406 Administration route switch7 (10.8 %)7 (13.7 %)0 (0 %)0.164 Duration of treatment  Total duration (weeks)6.0 (2.7--9.9)6.0 (2.9--9.7)5.8 (3.0--11.60.750  IV treatment duration (weeks)5.0 (2.9--9.7)5.0 (3.0--9.7)NANA  SC treatment duration (weeks)6.2 (3.9--21.4)NA5.3 (2.8--11.6)NA Pharmacological data  Number of dosages2.5 (2--3.3)3 (2--3)2 (2--3.8)0.891  Initial C~min~ (day 3 to 5, mg/L)11.7 (9.2--16.3)10.8 (8.6--15.2)13.8 (11.4--16.2)0.130   Initial C~min~ \>25 mg/L0 (0 %)0 (0 %)0 (0 %)NC   Initial C~min~ \<15 mg/L36 (73.5 %)29 (74.4 %)7 (70.0 %)1.000  Overdose (day 1 to 14)10 (15.6 %)8 (16.0 %)2 (14.3 %)1.000  Delay for C~min~ \> 15 mg/L (days)8.5 (6--13)9 (6--13)7 (4.5--9.5)0.259 Companion drugs  Rifampicin16 (24.6 %)12 (23.5 %)4 (28.6 %)0.732  Fluoroquinolone29 (44.6 %)20 (39.2 %)9 (64.3 %)0.131  Pristinamycin11 (16.9 %)11 (21.6 %)0 (0 %)0.102 Teicoplanin-related AE6 (10 %)4 (8.7 %)2 (14.3 %)0.617Follow-up and outcome Follow-up period (weeks)91.1 (50.6--182.6)98.0 (58.3--194.9)68.2 (40.7--100.3)0.112 One-month CRP level \< 10 mg/L17 (27.9 %)14 (28.0 %)3 (27.3 %)1.000 Treatment failure27 (41.5 %)21 (41.2 %)6 (42.9 %)1.000  Persisting infection18 (28.6 %)14 (28.0 %)4 (30.8 %)1.000  Relapse6 (9.7 %)6 (12.2 %)0 (0 %)0.328  Iterative surgery23 (35.9 %)19 (38.0 %)4 (28.6 %)0.754  BJI-related death1 (1.6 %)1 (2.0 %)0 (0 %)1.000  Superinfection13 (20.0 %)10 (19.6 %)3 (21.4 %)1.000*AE* adverse event, *BJI* bone and joint infection, *BMI* body mass index, *CCI* Charlson's comorbidity index, *C* ~*min*~ plasmatic teicoplanin trough concentration, *CRP* C-reactive protein, *Incl* Including, *IV* Intravenous, *MRSA* Methicillin-resistant Staphylococcus aureus, *ODI* orthopedic device-associated infection, *PJI* prosthetic joint infection, *SC* subcutaneous^a^ for orthopedic device-related infections

Teicoplanin prescription modalities {#Sec9}
-----------------------------------

Teicoplanin was used at the median dose of 5.7 (IQR, 4.7--6.5) mg/kg administrated in a single daily injection, after a loading dose (*n* = 55, 85.9 %) of 5 (IQR, 5--5) injections of 5.7 (IQR, 4.7--6.5) mg/kg/12 h. Median total duration of teicoplanin therapy was 6.0 (IQR, 2.7--9.9) weeks. Teicoplanin was mostly administrated *via* IV route (*n* = 51, 78.5 %), but 14 (21.5 %) cases were treated by SC route with no difference regarding prescription modalities (median dose, loading dose, duration) compared with IV-treated patients (Table [1](#Tab1){ref-type="table"}). The median number of SC injections per patient was 39.5 (IQR, 24.0--86.5), with a maximum of 600 mg of teicoplanin per injection. Seven switches in administration route were observed, all in patients initially receiving IV treatment. The main teicoplanin companion drugs were fluoroquinolones (44.6 %), rifampicin (24.6 %) and pristinamycin (16.9 %).

Pharmacological data {#Sec10}
--------------------

During the first 14 days of treatment, at least one C~min~ value was available in 59 patients, in whom a median of 2 (IQR, 2─3) dosages was performed during this period. An early C~min~ (on day 3, 4 or 5) was available in 44 patients and was under the therapeutic target of 15 mg/L in 73.5 % of them, with a median value of 11.7 mg/L. A C~min~ \>15 mg/L was finally obtained in only 39 (66.1 %) patients within the first 2 weeks of treatment, in a median delay of 9 (IQR, 6─13) days, without difference between the IV and SC routes of administration (Fig. [1](#Fig1){ref-type="fig"}). No difference was observed between patients who reached or not the therapeutic target of 15 mg/L (Additional file [1](#MOESM1){ref-type="media"}: Table S1).Fig. 1Comparison of median teicoplanin trough concentrations in intravenously- and subcutaneously-treated patients during the first 2 weeks of treatment. Data are presented as median and interquartile ranges of teicoplanin trough levels available each day after treatment initiation

During the first 2 weeks of treatment, an overexposure was observed in 8 patients who had a significantly older age (76.0 year-old, *p* = 0.007) and modified Charlson comorbidity index (7.5, *p* = 0.001) than those with no overexposure (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Their baseline renal function was more frequently impaired (50.0 %, *p* = 0.049).

Tolerance {#Sec11}
---------

Seven adverse events occurred in 6 (10.0 %) of the 60 included patients, consisting in 5 cutaneous rashes, 1 episode of headache, and one pancytopenia (Table [2](#Tab2){ref-type="table"}). IV and SC routes were implicated in four and one cases, respectively (*p* = 0.617). No difference was shown between patients presenting or not a teicoplanin-related AE, and no predictive factor could be highlighted and especially chronic renal failure, daily dose and early overdose (Additional file [2](#MOESM2){ref-type="media"}: Table S2). Of note, no severe AE was reported at the injection site in the SC group. The occurrence of an adverse event did not significantly impact outcome.Table 2Description of the seven teicoplanin-related adverse events observed in 6 of the 60 included patientsCaseModified CCIBJI typeAE subtypeCTCAE gradeRouteDosageDelayCompanion drugStopHospitalization (duration)Resolution15Acute osteomyelitisRash maculo-papular2IV12 mg/L7 daysNoneYesYes (3 days)Yes24Acute PJIRash maculo-papular2IVNo10 daysOxacillin\
ClindamycinYesNo (17 days)Yes30Acute VORash maculo-papular\
Pancytopenia3SCNo11 daysRifampicinYesNoYes45Chronic osteomyelitisHeadache1IV27.8 mg/L20 daysRifampicinYesNoYes52Chronic VORash maculo-papular3SCNo22 daysOfloxacinYesYes (4 days)Yes62Acute VORash maculo-papular2IVNo14 daysOfloxacinYesNoYes*AE* adverse event, *BJI* bone and joint infection, *CCI* Charlson's comorbidity index, *CTCAE* common terminology criteria for adverse events, *IV* Intravenous, *PJI* prosthetic joint infection, *SC* subcutaneous, *VO* vertebral osteomyelitis

Outcome {#Sec12}
-------

In a median follow-up of 91.1 (IQR, 50.6--182.6) weeks, 27 treatment failure were observed, including persisting infections (*n* = 18; 66.7 %), relapses (*n* = 6; 22.2 %) and/or superinfections (*n* = 13; 48.1 %), leading to iterative surgical procedure(s) in 23 (35.4 %) cases including two limb amputations. One sepsis-related death was observed.

In univariate analysis, pertinent variables associated with therapeutic failure with a *p*-value \<0.15 were inflammatory systemic disease (OR, 5.600; 95 % CI, 1.056--29.683), diabetes mellitus (OR, 5.143; 95 % CI, 0.951--27.826), and abscess (OR, 4.073; 95 % CI, 1.420--11.684). The return to baseline C-reactive protein value at 1 month was associated with a lower risk of treatment failure (OR, 0.214; 95 % CI, 0.051--0.852). In multivariate analysis, in situ abscess was independently associated with treatment failure (OR, 3.641; 95 % CI, 1.110--11.944) (Additional file [3](#MOESM3){ref-type="media"}: Table S3). Of note, teicoplanin administration route did not influence the outcome.

Discussion {#Sec13}
==========

Although teicoplanin is among the drugs of choice for the treatment of staphylococcal BJI, efficacy, safety and pharmacokinetics data in that specific setting are scarce. Thus, the present study provides relevant features with regards to staphylococcal BJI management. Our study is subjected to limitations BJI studies generally encounter such as the retrospective design coupled to the inherent lack of control patients. The limited patients' recruitment, the variety of infection types, surgical management and medical treatment approaches also constitute a limitation to generalisation.

These current difficulties in the field of BJI explain the limited and controversial data available on the efficacy of teicoplanin in staphylococcal BJI. In past studies, treatment success rate ranged from 53 to 91 % \[[@CR11]--[@CR14]\]. The low success rate observed in our study (60 %) may be explained by several factors. First, there is a significant selection bias as patients were recruited in a reference center dedicated to manage complex BJI with a high-risk of failure. In addition, most of past studies included native BJI with a relatively short follow-up (\<1 year). Finally, pharmacodynamics parameters may impact the outcome \[[@CR15], [@CR16]\]. In our study, a C~min~ reaching the therapeutic target of 15 mg/L was achieved in a quarter of cases at the first measurement (day 3 to 5) and in two thirds of patients within 2 weeks of treatment. The use of higher doses may improve these pharmacological parameters. In the study by LeFrock et al, the teicoplanin C~min~ averaged 10 mg/L after 6 days in patients receiving 6 mg/kg/day after 5 loading doses of 6 mg/kg/12 h compared to 20 mg/L from the third day in patients receiving 12 mg/kg/day after 5 loading doses of 12 mg/kg/12 h \[[@CR12]\]. If no difference was observed regarding osteomyelitis outcome, higher doses were associated with a better outcome among patients with native septic arthritis. Nevertheless, clinical outcome according to C~min~ was not an intended end-point in the study. Greenberg et al reported a favorable outcome in patients with a C~min~ \> 30 mg/L, but with no comparative data \[[@CR17]\]. It is our belief that the loading dose should be increased to 8 mg/kg/12 h to optimize trough concentrations, particularly in case when orthopedic implant is retained. Other determinants of therapeutic success had already been described, such as inflammatory systemic disease, diabetes and abscess \[[@CR18], [@CR19]\]. Conversely, our study was not associated with MRSA as a negative prognostic factor as found elsewhere \[[@CR20]\]. This last prognostic factor probably relies on the benefit of receiving anti-staphylococcal penicillins for a MSSA compared to glycopeptides \[[@CR21], [@CR22]\], which could not be highlighted in our series as all patients received teicoplanin, including those with MSSA infection. Finally, although all *S. aureus* isolates included in our study were tested susceptible to teicoplanin \[[@CR23]\], the exact MIC of each isolate was not available and could consequently not be challenged as an outcome predictor. As described with vancomycin, high teicoplanin MICs (i.e., \> 1.5 mg/L) have been associated with unfavorable outcome and higher mortality rate among teicoplanin-treated MRSA bacteremia \[[@CR24]\].

Regarding safety data, our results highlighted an excellent tolerance of teicoplanin with a 10 % incidence of AE, which is consistent with the toxicity rate of 9 to 18 % observed in other similar studies \[[@CR11], [@CR13], [@CR25]\]. However, the incidence of AE was probably been underestimated due to the retrospective nature of our study (memory bias for non-severe AE). Indeed, in the prospective study of LeFrock et al, the rate of AE was 35 %, requiring discontinuation of treatment in 17 % of the cases \[[@CR12]\]. Very few data support enhanced AE related to teicoplanin dose increase \[[@CR26]\]. LeFrock et *al* reported fever in 5.6 and 13.1 % of patients receiving 6 and 12 mg/kg/day of teicoplanin, respectively, with similar data regarding cutaneous rashes (7.6 and 15.4 %, respectively) \[[@CR12]\]. In our study, teicoplanin daily dose and overexposure within 2 weeks of treatment were not predictors of AE. In two other studies, a dose increase from 400 to 600 mg/day was not associated with an increased risk of toxicity \[[@CR27], [@CR28]\].

The description of subcutaneous administration of teicoplanin is another important highlight of our study, showing similar efficacy, safety and pharmacokinetics characteristics compared to IV administration. The retrospective design may result in underestimating non-serious AE such as injection site reactions. In a recent prospective evaluation of SC teicoplanin in 30 patients, 90 % of patients presented moderate local AE (grades 1--2) and no severe local reaction (grade ≥3) \[[@CR29]\]. Of note, none of our patients had SC teicoplanin infusion exceeding 600 mg, reported as an independent risk factor for local reaction in the study by El Samad et al \[[@CR29]\]. Subcutaneous teicoplanin may be particularly useful in patients with BJI eligible for OPAT achieving efficacy and allowing cost reduction \[[@CR30], [@CR31]\]. Some authors have even proposed a 3-injections weekly regimen with a satisfactory success rate and an estimated saving of \$60,000 per episode of BJI \[[@CR32], [@CR33]\]. However, a study has tempered this suggestion by showing a non-significant trend toward a higher risk of failure in patients treated by teicoplanin for BJI \[[@CR34]\]. Further studies, optimally with a prospective and controlled design, are warranted to assess both the risk-benefit as well as the cost-benefit of teicoplanin in staphylococcal BJI.

Conclusion {#Sec14}
==========

At the dose of 6 mg/kg/24 h after a loading dose of 5 injections of 6 mg/kg/12 h, teicoplanin appeared as a well-tolerated option in the treatment of *S. aureus* BJI, and may be recommended as an alternative to vancomycin in patients with MRSA infection or with intolerance to betalactam antibiotics. The use of higher doses must be discussed in order to optimize pharmacokinetic parameters of which clinical pertinence remains to be demonstrated. However, we believe that the loading dose should be increased to more rapidly reach the therapeutic target, which can be crucial for outcome of acute ODI with implant retention. Furthermore, subcutaneous administration of teicoplanin showed similar results in terms of efficacy, tolerance and pharmacokinetics compared to the intravenous administration, which encourage its use in OPAT. However, the implication of a multidisciplinary referral center for the management of complex BJI is needed to ensure a successful outpatient management, as suggested by the need for a close clinical, biological and pharmacological monitoring, particularly during the first 2 weeks of treatment when the majority of side effects occur.

Additional files {#Sec15}
================

Additional file 1: Table S1.Comparison of patients presenting or not a teicoplanin overdose (teicoplanin plasmatic trough concentration \> 25 mg/L) and reaching or not the therapeutic concentration of 15 mg/L during the first 14 days of treatment (DOCX 19 kb) Additional file 2: Table S2.Adverse events determinants in the 60 included patients treated by teicoplanin for a *Staphylococcus aureus* bone and joint infection (DOCX 22 kb) Additional file 3: Table S3.Treatment failure determinants of the 65 included episodes of *Staphylococcus aureus* bone and joint infection (DOCX 25 kb)
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